CHARLES, Mark David,EKWURU, Chukuemeka Tennyson,FINLAY, Maurice Raymond Verschoyle,NISSINK, Johannes Wilhelmus Maria,RAUBO, Piotr Antoni,WINTER, Jonathan James Gordon
申请号：
TN2016000511
公开号：
TN2016000511A1
申请日:
2015.05.27
申请国别(地区):
TN
年份:
2018
代理人:
摘要：
The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R<；sup>；1<；/sup>； and R<；sup>；2 <；/sup>；have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof； pharmaceutical compositions comprising such compounds and salts； kits comprising such compounds and salts； methods of manufacture of such compounds and salts； intermediates useful in the manufacture of such compounds and salts； and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts
